COLDIFED-P price in UAE

Overview

Welcome to Dwaey, specifically on COLDIFED-P Syrup page.
This medicine contains an important and useful components, as it consists of Pseudoephedrine HCl, Triprolidine HCl, Paracetamol.
COLDIFED-P is available in the market in concentration 30mg, 1.25mg, 120mg/5ml and in the form of Syrup.

LIFEPHARMA FZE is the producer of COLDIFED-P and it is imported from UAE, The most popular alternatives of COLDIFED-P are listed downward .

Mode Of Action

Triprolidine is a potent competitive histamine H1-receptor antagonist with mild sedating and antimuscarinic properties. Pseudoephedrine, an alpha- and beta-adrenergic receptor agonist, mediates vasoconstriction via direct stimulation of alpha-adrenergic receptors of the respiratory mucosa. Dextromethorphan is a centrally acting cough suppressant which acts on the cough centre in the medulla.

Indication

Flu
Colds
Runny nose
Dry coughs
Non-productive cough
Nasal congestion

Precaution

3rd trimester of pregnancy; atopic childn; child <1 yr; sedated or debilitated patients; patients confined to supine position; history of asthma. Moderate to severe renal impairment; liver disease.

Side Effects

Dizziness
GI disturbances.

Contra indication

Patients at risk of developing resp failure. During an acute attack. Patients receiving MAOI or for 2 wk after discontinuing them. Persistent or chronic cough.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Dextromethorphan: Tricyclic antidepressants (TCAs), antipsychotics, anxiolytics and hypnotics, cimetidine, ciprofloxacin, domperidone, metoclopramide, mexiletine, CYP2D6 inhibitors, ritonavir, alcohol. Potentially Fatal: Memantine, moclobemide. Triprolidine + Pseudoephedrine: Increased BP with other sympathomimetic agents (e.g. decongestants, TCA, appetite suppressants). Reduced hypotensive effects of methyldopa, ?- and ?-adrenergic blockers. Increased side effects (e.g. somnolence, agitation) with atomoxetine. Potentially Fatal: Increased risk of hypertensive crisis with furazolidine, avoid concurrent use. Increased risk of hypertensive crisis with MAOIs; avoid concurrent use or within 2 wk after stopping MAOIs. Increased risk of psychosis with bromocriptine.